相关实验视频

Updated: Jan 13, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

在不同免疫亚型的小瘤乳腺癌中预后和化疗疗效率:基于SEER的研究

Hong Mei Wang¹, Yue Hui Zhou², Gu Bin Lin³

¹Department of Thyroid and Breast Surgery, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China.

Translational cancer research

|January 9, 2026

概括

患有T1mi/a-bN1激素受体阴性,人体表皮生长因子受体2-阳性 (HR-HER2+) 亚型的小瘤乳腺癌患者面临更高的死亡风险. 辅助化疗对大多数小瘤乳腺癌患者,特别是某些子组,提供了有限的生存益处.

科学领域:

在瘤学瘤学.
癌症研究癌症研究
临床医学临床医学

背景情况:

对于淋巴结转移的小瘤乳腺癌患者,存在明显的生存率.
有限的研究存在于小瘤乳腺癌患者考虑免疫亚型和淋巴结转移.
了解预后因素对于优化治疗策略至关重要.

研究的目的:

根据免疫亚型和淋巴结转移,研究小瘤乳腺癌患者的生存结果.
评估辅助化疗在小瘤乳腺癌患者不同亚组的疗效.
确定需要量身定制的治疗方法的高风险子组.

主要方法:

来自SEER数据库的小瘤乳腺癌患者数据的回顾性分析.
多变量考克斯比例危险模型用于预后因素分析.
根据瘤阶段 (T),淋巴结转移 (N) 和免疫亚型 (HR/HER2状态) 分层的生存分析.

主要成果:

T1cN2+阶段表明死亡风险最高.
T1mi/a-bN1激素受体阴性,人体表皮生长因子受体2-阳性 (HR-HER2+) 患者的整体存活率 (OS) 和乳腺癌特异性存活率 (BCSS) 显著降低.
在小瘤乳腺癌患者中,辅助化疗 (AC) 改善了OS (HR=0.78,P<0.001),但没有BCSS (HR=1.1,P=0.11);然而,它在特定亚组中没有显著的生存益处 (pT1mi/a-bN0-1 HR+HER2-和pT1mi/a-bN0 HR-HER2-/HR+HER2+).

结论:

T1mi/a-bN1 HR-HER2+亚组代表了小瘤乳腺癌的高风险组.
小瘤乳腺癌患者通常从辅助化疗中获得有限的益处.
对于特定的患者亚组,AC可能是不必要的,包括pT1mi/a-bN0-1 HR+HER2-和pT1mi/a-bN0 HR-HER2-/HR+HER2+.

关键词:

这是一个小瘤.监测,流行病学和最终结果数据库 (SEER数据库)辅助化疗 (AC) 是一种辅助化疗.乳腺癌乳腺癌乳腺癌淋巴结转移是淋巴结的转移.

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...